415 related articles for article (PubMed ID: 30369184)
41. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
42. Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation.
Lee HG; Kim SY; Kim I; Kim YK; Kim JA; Kim YS; Lee HS; Park J; Kim SJ; Shim H; Eom HS; Park BB; Lee J; Park SK; Cheong JW; Park KW
Blood Res; 2015 Sep; 50(3):160-6. PubMed ID: 26457283
[TBL] [Abstract][Full Text] [Related]
43. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
44. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
45. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.
Chaiwatanatorn K; Stamaratis G; Opeskin K; Firkin F; Nandurkar H
Leuk Lymphoma; 2009 Oct; 50(10):1666-75. PubMed ID: 19757311
[TBL] [Abstract][Full Text] [Related]
46. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
Batty N; Ghonimi E; Feng L; Fayad L; Younes A; Rodriguez MA; Romaguera JE; McLaughlin P; Samaniego F; Kwak LW; Hagemeister FB
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):15-8. PubMed ID: 23137719
[TBL] [Abstract][Full Text] [Related]
47. A Comparison of Clinical Prognostic Indices in Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with a Pegylated Liposomal Doxorubicin Combination Regimen in China.
Gao H; Xu Y; Liu Y; Mi L; Wang X; Liu W; Zhu J; Song Y
Cancer Manag Res; 2022; 14():2711-2721. PubMed ID: 36133738
[TBL] [Abstract][Full Text] [Related]
48. [Relationship between p53 rs1625895 polymorphism and prognosis in diffuse large B-cell lymphoma].
Tian Y; Zhu J
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):791-796. PubMed ID: 31624379
[TBL] [Abstract][Full Text] [Related]
49. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
50. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
51. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
52. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
53. Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores.
Lee H; Kim YR; Kim SJ; Park Y; Eom HS; Oh SY; Kim HJ; Kang HJ; Lee WS; Moon JH; Won YW; Kim TS; Kim JS
Ann Hematol; 2017 Nov; 96(11):1873-1881. PubMed ID: 28831584
[TBL] [Abstract][Full Text] [Related]
54. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
55. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
[TBL] [Abstract][Full Text] [Related]
56. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.
Procházka V; Pytlík R; Janíková A; Belada D; Sálek D; Papajík T; Campr V; Fürst T; Furstova J; Trněný M
PLoS One; 2014; 9(7):e102594. PubMed ID: 25058337
[TBL] [Abstract][Full Text] [Related]
57. [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].
Zhao SX; Han Y; Zhu Q; Wang Q; Zhang WJ; Chen XC; Sun AN; Jin ZM; Qiu HY; Tang XW; Fu ZZ; He GS; Miao M; Ma X; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):623-7. PubMed ID: 23815910
[TBL] [Abstract][Full Text] [Related]
58. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
59. [Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
Huang HW; Jiang YB; Fu TW; Xu T; Chen XC; Jin ZM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):602-6. PubMed ID: 27535862
[TBL] [Abstract][Full Text] [Related]
60. Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Hishima T; Omuro Y
Ann Hematol; 2018 Jun; 97(6):999-1007. PubMed ID: 29427185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
